Azacytidine as a novel agent in the treatment of acute lymphoblastic leukemia

Leukemia and Lymphoma

Volumn 52, Issue 1, 2011, Pages 134-136

  Paulson, Kristjan ^a   Kumar, Rajat ^a   Ahsanuddin, Arshad ^a   Seftel, Matthew D ^a  

^a UNIVERSITY OF MANITOBA   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

AZACITIDINE; CYCLOPHOSPHAMIDE; DEXAMETHASONE; MERCAPTOPURINE; PREDNISONE; VINCRISTINE;

ACUTE LYMPHOBLASTIC LEUKEMIA; AGED; ARTICLE; BONE MARROW BIOPSY; CASE REPORT; CYTOGENETICS; DRUG TOLERABILITY; EPIGENETICS; FEBRILE NEUTROPENIA; FEMALE; GENE DELETION; HUMAN; MULTIPLE CYCLE TREATMENT; PANCYTOPENIA; PATHOGENESIS; PRE B LYMPHOCYTE; PRIORITY JOURNAL; REFRACTORY CYTOPENIA WITH MULTILINEAGE DYSPLASIA; THROMBOCYTE COUNT;

ANTIMETABOLITES, ANTINEOPLASTIC; ANTINEOPLASTIC AGENTS; AZACITIDINE; FEMALE; HUMANS; MIDDLE AGED; PANCYTOPENIA; PRECURSOR CELL LYMPHOBLASTIC LEUKEMIA-LYMPHOMA; PROGNOSIS;

EID: 78651270112     PISSN: 10428194     EISSN: 10292403     Source Type: Journal    
DOI: 10.3109/10428194.2010.512965     Document Type: Article

References (11)

1. Fenaux P, Mufti GJ, Hellstrom-Lindberg E, et al. Efficacy of azacitidine compared with that of conventional care regimens in the treatment of higher-risk myelodysplastic syndromes: a randomised, open-label, phase III study. Lancet Oncol 2009;10:223-232.
2. Naithani R, Kumar R, Saxena R, Mahapatra M. Transformation of myelodysplastic syndrome to T-cell acute lymphoblas-tic leukemia in a young adult. Pediatr Hematol Oncol 2009;26:100-102.
3. Disperati P, Ichim CV, Tkachuk D, Chun K, Schuh AC, Wells RA. Progression of myelodysplasia to acute lympho-blastic leukaemia: implications for disease biology. Leuk Res 2006;30:233-239.
4. Roman-Gomez J, Jimenez-Velasco A, Barrios M, et al. Poor prognosis in acute lymphoblastic leukemia may relate to promoter hypermethylation of cancer-related genes. Leuk Lymphoma 2007;48:1269-1282.
5. Román-Gómez J, Cordeu L, Agirre X, et al. Epigenetic regulation of Wnt-signaling pathway in acute lymphoblastic leukemia. Blood 2007;109:3462-3469.
6. Garcia-Manero G, Jeha S, Daniel J, et al. Aberrant DNA methylation in pediatric patients with acute lymphocytic leukemia. Cancer 2003;97:695-702. (Pubitemid 36131078)
7. Fenaux P. Inhibitors of DNA methylation: beyond myelo-dysplastic syndromes. Nat Clin Pract Oncol 2005;2:S36-S44.
8. Hoshino K, Quintás-Cardama A, Yang H, Sanchez-Gonzalez B, Garcia-Manero G. Aberrant DNA methylation of the Src kinase Hck, but not of Lyn, in Philadelphia chromosome negative acute lymphocytic leukemia. Leukemia 2007;21:906-911.
9. Kuang SQ, Tong WG, Yang H, et al. Genome-wide identification of aberrantly methylated promoter associated CpG islands in acute lymphocytic leukemia. Leukemia 2008;22:1529-1538.
10. Saiki JH, McCredie KB, Vietti TJ, et al. 5-azacytidine in acute leukemia. Cancer 1978;42:2111-2114.
11. Yánez L, Bermúdez A, Richard C, Bureo E, Iriondo A. Successful induction therapy with decitabine in refractory childhood acute lymphoblastic leukemia. Leukemia 2009;23: 1342-1343.